Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 7,968 Shares

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 7,968 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $382,464.00. Following the completion of the transaction, the chief executive officer now directly owns 581,584 shares of the company’s stock, valued at approximately $27,916,032. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Twist Bioscience Price Performance

NASDAQ:TWST traded down $2.77 during trading hours on Wednesday, hitting $42.49. 962,117 shares of the company traded hands, compared to its average volume of 941,048. Twist Bioscience Co. has a twelve month low of $18.59 and a twelve month high of $60.90. The firm has a 50-day moving average of $43.86 and a 200 day moving average of $45.95.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds have recently made changes to their positions in TWST. Signaturefd LLC increased its position in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC acquired a new position in Twist Bioscience in the second quarter worth about $43,000. Blue Trust Inc. grew its stake in shares of Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after purchasing an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in Twist Bioscience during the second quarter worth $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. upped their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Leerink Partners increased their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Barclays lowered their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Evercore ISI upped their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Robert W. Baird lifted their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and an average price target of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.